There is a wealth of opportunity for SMEs to grow and diversify, and to reflect the multiplicity of existing life science businesses in Greater Birmingham we have listed a selection here.
The Binding Site Group Ltd dates back to the early 1970s when a group of researchers within the Medical School of Birmingham University first started looking at innovative ways of producing antibodies. They founded a private company which has evolved into Binding Site and is now one of the largest independent providers of specialist in vitro diagnostic tests and equipment in the UK and the World leader in special protein testing.
Today it employs more than 700 people across all major markets worldwide, with offices in the UK, USA, Belgium, Czech Republic, France, Germany, Italy and Spain.
Binding Site exports ~90% of the products manufactured at its Birmingham head office and international trade has more than doubled between 2010 and 2015, with total worldwide Group revenues last year exceeding £80million. Most recently, Binding Site were recognised for their exceptional achievement in International Trade with a 2016 Queen’s Award for Enterprise.
In 2011, Binding Site relocated to new headquarters in Birmingham city centre, having had its roots at the University.
The company has opted to stay in the region not just because of its strong links with the University of Birmingham, but access to a multi-cultural population mix as well as excellent transport links.
Abingdon Health is a UK based medical diagnostics group focused on developing, manufacturing and commercialising point of care immunoassay tests for disorders of the immune system. Their initial focus is on developing rapid tests for haematology oncology and specifically B cell dyscrasias.
They launched the world’s first rapid diagnostic device in multiple myeloma in March 2015, Seralite®– FLC. The contract services team provides assay development and manufacturing services for customers looking to transfer existing laboratory based assays to a lateral flow format. They take projects from initial concept through to transfer to production. Abingdon Health are located in The BioHub Birmingham®.
Celentyx was founded upon applied research originating from the world-renowned Medical Research Council (UK) Centre for Immune Regulation, situated in the University of Birmingham Medical School.
The founders, Professor Nicholas Barnes and Professor John Gordon were amongst the first to recognise that many neurotransmitters also modify the immune system and are internationally recognised authorities in this relatively new field of neuroimmunopharmacology.
Their development of ImmuKnowlogy™ provides an efficient toolbox of routine and sophisticated methodologies to aid pharma R&D by understanding the effect of small molecule and biological candidate therapeutics upon the human immune system in health and disease.